Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

VEGF-A Expression Correlates with TP53 Mutations in Non-Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy.

Cancer research - 1 Apr 2015

Schwaederlé Maria, Lazar Vladimir, Validire Pierre, Hansson Johan, Lacroix Ludovic, Soria Jean-Charles, Pawitan Yudi, Kurzrock Razelle

Abstract excerpt

Bevacizumab is one of the most widely used antiangiogenic drugs in oncology, but the overall beneficial effects of this VEGF-A targeting agent are relatively modest, in part due to the lack of a biomarker to select patients most likely to respond favorably. Several molecular aberrations in cancer influence angiogenesis, including mutations in the tumor suppressor gene TP53, which occur frequently in many human...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Angiogenesis Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bevacizumab

Share to Carcinoma, Squamous Cell

Share to Lung Neoplasms

Share to Transcriptome

Share to Tumor Suppressor Protein p53

Share to Vascular Endothelial Growth Factor A

Source

Identifiers

PMID: 25672981
DOI: 10.1158/0008-5472.CAN-14-2305

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

VEGF-A Expression Correlates with TP53 Mutations in Non-Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy.PMID 25672981Read ↗

TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics.Semantic proximity Read ↗

Association of TP53 Mutations with Response to Anlotinib Treatment in Advanced Non-Small Cell Lung CancerSemantic proximity Read ↗

Effects of Tp53 Gene Mutations on the Survival of Non-Small Cell Lung Cancer (NSCLC); A Short ReviewSemantic proximity Read ↗

Predictive and Prognostic Potential of TP53 in Patients With Advanced Non-Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901).Semantic proximity Read ↗

The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for TherapySemantic proximity Read ↗

The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base.Semantic proximity Read ↗

TP53 somatic mutations are associated with poor survival in non-small cell lung cancer patients who undergo immunotherapySemantic proximity Read ↗

The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer.Semantic proximity Read ↗

Aberrant p53 Expression Correlates With Expression of Vascular Endothelial Growth Factor mRNA and Interleukin-8 mRNA and Neoangiogenesis in Non-Small-Cell Lung CancerSemantic proximity Read ↗

Potential tumorigenic programs associated with TP53 mutation status reveal role of VEGF pathway.Semantic proximity Read ↗

Role of VEGFA/VEGFR2 signaling in predicting clinical outcomes of EGFR-TKI treatment in EGFR-mutant non-small cell lung cancer.Semantic proximity Read ↗

Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer Patients With EGFR Mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.